Case Reports

High-dose intravenous immunoglobulin may be an efficient treatment option for patients with late-onset high-grade immune effector cell-associated hematotoxicity refractory to standard therapies

Department of Internal Medicine H, Rambam Health Care Campus, Haifa
Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa
Section of Clinical Pharmacology and Toxicology, Rambam Health Care Campus, Haifa, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa
Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa
Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa
Blood Bank and Platelet Immunology Laboratory, Rambam Health Care Campus, Haifa
Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa
Department of Internal Medicine H, Rambam Health Care Campus, Haifa, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa
Department of Internal Medicine H, Rambam Health Care Campus, Haifa
Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa
Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa
Haematologica Early view Jan 9, 2025 https://doi.org/10.3324/haematol.2024.286714